Tyra Biosciences Inc (NASDAQ:TYRA) — Market Cap & Net Worth
Market Cap & Net Worth: Tyra Biosciences Inc (TYRA)
Tyra Biosciences Inc (NASDAQ:TYRA) has a market capitalization of $1.37 Billion ($1.37 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7573 globally and #2284 in its home market, demonstrating a -11.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tyra Biosciences Inc's stock price $25.43 by its total outstanding shares 53867115 (53.87 Million). Also see Tyra Biosciences Inc total assets for a full breakdown of the balance sheet.
Tyra Biosciences Inc Market Cap History: 2021 to 2026
Tyra Biosciences Inc's market capitalization history from 2021 to 2026. Data shows change from $757.91 Million to $1.37 Billion (-0.44% CAGR). Also see Tyra Biosciences Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Tyra Biosciences Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.05% | #219 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #842 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.07% | #127 of 263 |
Weight: Tyra Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tyra Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tyra Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Tyra Biosciences Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TYRA by Market Capitalization
Companies near Tyra Biosciences Inc in the global market cap rankings as of September 17, 2026. Review TYRA goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Tyra Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Tyra Biosciences Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Tyra Biosciences Inc's market cap moved from $757.91 Million to $ 1.37 Billion, with a yearly change of -0.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.37 Billion | -3.27% |
| 2025 | $1.42 Billion | +89.14% |
| 2024 | $748.75 Million | +0.36% |
| 2023 | $746.06 Million | +82.24% |
| 2022 | $409.39 Million | -45.98% |
| 2021 | $757.91 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Tyra Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.37 Billion USD |
| MoneyControl | $1.37 Billion USD |
| MarketWatch | $1.37 Billion USD |
| marketcap.company | $1.37 Billion USD |
| Reuters | $1.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more